Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline.
|
$ 2000
|
|
|
Dyskinesia – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Dyskinesia - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for D
|
$ 2000
|
|
|
Lupus Nephritis – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Lupus Nephritis - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic develop
|
$ 2000
|
|
|
Metabolic Disorders – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Metabolic Disorders - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic
|
$ 2000
|
|
|
Opium (Opioid) Addiction – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Opium (Opioid) Addiction - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the t
|
$ 2000
|
|
|
Actinic Keratosis – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Actinic Keratosis - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic dev
|
$ 2000
|
|
|
Pertussis – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Pertussis - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Per
|
$ 2000
|
|
|
Smallpox – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Smallpox - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Small
|
$ 2000
|
|
|
Tetanus – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Tetanus - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Tetanus
|
$ 2000
|
|
|
Diabetic Neuropathy – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Diabetic Neuropathy - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic
|
$ 2000
|
|
|
Psoriatic Arthritis – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Psoriatic Arthritis - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic
|
$ 2000
|
|
|
Alopecia – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Alopecia - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Alope
|
$ 2000
|
|
|
Constipation – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Constipation - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development f
|
$ 2000
|
|
|
Amyloidosis – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Amyloidosis - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for
|
$ 2000
|
|
|
Colitis – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Colitis - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Colitis
|
$ 2000
|
|
|
Dermatitis – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Dermatitis - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for D
|
$ 2000
|
|
|
Macular Edema – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Macular Edema - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development
|
$ 2000
|
|
|
Polio – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Polio - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Polio, comp
|
$ 2000
|
|
|
Severe Psoriasis – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Severe Psoriasis - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic devel
|
$ 2000
|
|
|
Chronic Back Pain – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Chronic Back Pain - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic dev
|
$ 2000
|
|
|